396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of oncology

Topics

Biology

Internal Medicine

Medicine

Molecular Biology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.annonc.2024.05.311